Key result
Prasugrel and ticagrelor are preferred over clopidogrel for dual antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Why the study?
Does prasugrel or ticagrelor improve effectiveness and safety compared to clopidogrel in patients with acute coronary syndrome?
Does prasugrel or ticagrelor improve effectiveness and safety compared to clopidogrel in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Prasugrel and ticagrelor are recommended over clopidogrel for dual antiplatelet therapy in ACS patients, but further data is needed to directly compare their efficacy and safety.
Dual antiplatelet therapy (acetylsalicylic acid and platelet P2Y12 receptor antagonist) is a standard component of treatment of any type of acute coronary syndrome, independently of perfusion and the chosen treatment strategy. Due to certain limitations of clopidogrel as the 2nd component of dual antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention, the possibility of using prasugrel or ticagrelor should be considered first. Their effectiveness is higher than clopidogrel’s, as was demonstrated in large clinical trials. As a result, prasugrel and ticagrelor were included in all major international and Russian guidelines on treatment of this category of patients with the same class and level of evidence. Currently, there’re no data from any finished large randomized clinical trials of sufficient statistical power directly comparing the effectiveness and safety of prasugrel and ticagrelor. Therefore, careful analysis of the accumulated data on the safety and effectiveness of each drug including meta-analyses and registries is necessary for providing the best care for every individual patient.
No takes yet. Share an insight, caveat, or question.
Константинова et al. (2018) conducted an editorial in Acute coronary syndrome. Prasugrel and Ticagrelor vs. Clopidogrel was evaluated. Prasugrel and ticagrelor are preferred over clopidogrel for dual antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: